This is an archive of papers published by the staff and faculty of Fox Chase Cancer Center. For questions about content, please contact Talbot Research Library
Last updated on
Rini BI , Plimack ER , Takagi T , Elson P , Wood LS , Dreicer R , Gilligan T , Garcia J , Zhang Z , Kaouk J , Krishnamurthi V , Stephenson AJ , Fergany A , Klein EA , Uzzo RG , Chen DY , Campbell SC
A Phase II Study of Pazopanib in Patients with Localized Renal Cell Carcinoma to Optimize Preservation of Renal Parenchyma
J Urol. 2015 Aug;194(2) :297-303
PMID: 25813447 URL: https://www.ncbi.nlm.nih.gov/pubmed/25813447
AbstractPURPOSE: Preservation of renal function is prioritized during surgical management of localized renal cell carcinoma. VEGF targeted agents can downsize tumors in metastatic renal cell carcinoma and may do the same in localized renal cell carcinoma, allowing for optimal preservation of renal parenchyma associated with partial nephrectomy. MATERIALS AND METHODS: Localized clear cell renal cell carcinoma patients meeting 1 or both of the following criteria were enrolled in a prospective phase II trial, including radical or partial nephrectomy likely to yield a glomerular filtration rate of less than 30 ml/minute/1.73 m(2), or partial nephrectomy high risk due to high complexity (R.E.N.A.L. 10 to 12) or tumor adjacent to hilar vessels. Pazopanib (800 mg once daily) was administered for 8 to 16 weeks with repeat imaging at completion of therapy, followed by surgery. RESULTS: A total of 25 patients enrolled with a median tumor size of 7.3 cm and a median R.E.N.A.L. score of 11. Of index lesions 80% were high complexity and 56% of patients had a solitary kidney. Patients received a median of 8 weeks of pazopanib. The median interval from treatment start to surgery was 10.6 weeks. R.E.N.A.L. score decreased in 71% of tumors and 92% of patients experienced a reduction in tumor volume. Six of 13 patients for whom partial nephrectomy was not possible at baseline were able to undergo partial nephrectomy after treatment. The mean parenchymal volume that could be saved with surgery increased from an estimated 107 to 173 cc (p = 0.0015). In 5 patients a urine leak developed, which was managed conservatively, and 7 received a transfusion, of whom 1 required embolization. CONCLUSIONS: Neoadjuvant pazopanib resulted in downsizing localized renal cell carcinoma, allowing for improved preservation of renal parenchyma and enabling partial nephrectomy in a select subset of patients who would otherwise require radical nephrectomy.
NotesRini, Brian I Plimack, Elizabeth R Takagi, Toshio Elson, Paul Wood, Laura S Dreicer, Robert Gilligan, Timothy Garcia, Jorge Zhang, Zhiling Kaouk, Jihad Krishnamurthi, Venkatesh Stephenson, Andrew J Fergany, Amr Klein, Eric A Uzzo, Robert G Chen, David Y T Campbell, Steven C eng Clinical Trial, Phase II Randomized Controlled Trial J Urol. 2015 Aug;194(2):297-303. doi: 10.1016/j.juro.2015.03.096. Epub 2015 Mar 23.